Navigation Links
InspireMD Reports Financial Results for Quarter Ended September 30, 2013
Date:11/11/2013

eptember 30, 2013 Financial ResultsRevenue for the quarter ended September 30, 2013 was $1.6 million, an increase of 205% compared to $0.5 million for the same period in 2012.  The increase year over year reflects the positive impact of recent steps taken to stabilize the global distribution strategy and the early success of targeted selling activities in Brazil as well as select European countries.

Gross profit for the quarter ended September 30, 2013 totaled $0.8 million, an increase of 187% compared to $0.3 million for same period in 2012. The increase in gross profit is attributable to an increase in revenue of approximately $1.1 million, as described above, partially offset by an increase in cost of revenues of approximately $0.5 million. Gross margin for the three months ended September 30, 2013 was 51.7%, a decrease from 54.8% in the three months ended September 30, 2012. If the non-recurring effects of the consolidation of our manufacturing facilities in the three months ended September 30, 2013 are removed, gross margin for the three months ended September 30, 2013 would have been 63.1%.

Total operating expenses for the quarter ended September 30, 2013 were $4.7 million, an increase of 31.7% compared to $3.6 million for the same period in 2012. The increase was primarily due to an increase in startup costs associated with initiating the MASTER II trial, as well as increased sales and marketing expenses, as the Company begins to build the appropriate sales infrastructure for future growth.

The loss from operations for the quarter ended September 30, 2013 was $3.9 million, an increase of 18.4% compared to a loss of $3.3 million for the same period in 2012.

Total financial expenses for the quarter ended September 30, 2013 were $0.1 million, a decrease of 98.6% compared to $4.2 million in the same period in 2012. The decrease in financial expenses resulted primarily from the absence of any non-cash revaluations of our warrants
'/>"/>

SOURCE InspireMD
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. InspireMD Announces First Quarter 2012 Financial Results
2. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
3. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
4. InspireMD to Present at Harvard Investors Group on June 27 in New York
5. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
6. InspireMD Reports Results For Period Ending Sept. 30, 2012
7. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
8. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
9. InspireMD Reports Results for Period Ended Dec. 31, 2012
10. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
11. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 Endo International plc (NASDAQ: ... revenues of $719 million, an increase of 1 percent ... Endo reported net income of $21 million in the ... million in the second quarter of 2013.  As detailed ... for the three months ended June 30, 2014 increased by ...
(Date:7/31/2014)... July 31, 2014 Marken announced today the ... to meet the clinical trial logistics growth in Central ... expanded facility will continue to serve as a regional ... and from the region, and will provide additional storage ... will combine its office and warehouse into a single ...
(Date:7/31/2014)... , 31 juli 2014 De Pfizer ... een rekruteringscampagne voor gezonde vrijwilligers van Japanse komaf voor ... gevestigde PCRU is één van twee onderzoekseenheden ... als ideaal levens te verbeteren door de ontdekking en ... de PCRU op zoek naar mannen en vrouwen van ...
Breaking Medicine Technology:Endo Reports Second Quarter Financial Results 2Endo Reports Second Quarter Financial Results 3Endo Reports Second Quarter Financial Results 4Endo Reports Second Quarter Financial Results 5Endo Reports Second Quarter Financial Results 6Endo Reports Second Quarter Financial Results 7Endo Reports Second Quarter Financial Results 8Endo Reports Second Quarter Financial Results 9Endo Reports Second Quarter Financial Results 10Endo Reports Second Quarter Financial Results 11Endo Reports Second Quarter Financial Results 12Endo Reports Second Quarter Financial Results 13Endo Reports Second Quarter Financial Results 14Endo Reports Second Quarter Financial Results 15Endo Reports Second Quarter Financial Results 16Endo Reports Second Quarter Financial Results 17Endo Reports Second Quarter Financial Results 18Endo Reports Second Quarter Financial Results 19Endo Reports Second Quarter Financial Results 20Endo Reports Second Quarter Financial Results 21Endo Reports Second Quarter Financial Results 22Endo Reports Second Quarter Financial Results 23Endo Reports Second Quarter Financial Results 24Endo Reports Second Quarter Financial Results 25Endo Reports Second Quarter Financial Results 26Endo Reports Second Quarter Financial Results 27Endo Reports Second Quarter Financial Results 28Endo Reports Second Quarter Financial Results 29Endo Reports Second Quarter Financial Results 30Endo Reports Second Quarter Financial Results 31Endo Reports Second Quarter Financial Results 32Marken Expands Miami Regional Logistics Center 2Gezonde vrijwilligers van Japanse komaf gezocht voor deelname aan Fase I klinisch onderzoek 2
... Genetic Technologies Limited (ASX: GTG; NASDAQ: ... agreement to jointly develop a new cancer profiling product ... Under the collaboration Genetic Technologies will use ... world-leading pharmaceutical company to develop specific and novel genetic ...
... If your medicine has expired, it may not provide ... FDA pharmacist Ilisa Bernstein explains how expiration dates help ... work as intended. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) ... Sign up for e-mail notices of new FDA Consumer ...
Cached Medicine Technology:GTG Announces New Product Collaboration with Global Pharmaceutical Company for Companion Diagnostics in Oncology 2
(Date:7/31/2014)... (PRWEB) July 31, 2014 T.E.N., ... relationship-marketing firm, honored finalists and winners Wednesday evening, ... Forum and Awards Gala at the Westin St. ... director of information security for the BlackLine Systems, ... the Year Award winner for the ISE® West ...
(Date:7/31/2014)... Amy Norton HealthDay ... Babies born with so-called "bubble boy" disease can often be ... -- but early treatment is critical, a new study finds. ... known, actually refers to a group of rare genetic disorders ... at high risk of severe infections. The term "bubble ...
(Date:7/31/2014)... 31, 2014 (HealthDay News) -- Recovery time after surgery ... known as statins, according to a new study. ... affect the body,s inflammatory response, reducing the amount of ... seemed to be particularly true among people who tend ... of the most widely prescribed medications in the world. ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 ... to reach $702m by 2020, increasing slowly ... market will be driven by: the rising ... incurred by government agencies, such as Medicare, ... adoption of innovative technologies such as flow ...
(Date:7/31/2014)... July 31, 2014 -- A new study by researchers ... a peptide called caerulein can convert existing cells in ... diabetes-insulin-producing beta cells. The study, published online July 31 ... new approach to treating the estimated 3 million people ... with type 1 diabetes. , "We have found a ...
Breaking Medicine News(10 mins):Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 2Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 3Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 4Health News:Early Stem Cell Transplant Vital in 'Bubble Boy' Disease 2Health News:Early Stem Cell Transplant Vital in 'Bubble Boy' Disease 3Health News:Cholesterol Drugs May Speed Healing After Surgery 2Health News:US Neurovascular Interventions Market Worth $702m by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:US Neurovascular Interventions Market Worth $702m by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:US Neurovascular Interventions Market Worth $702m by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:US Neurovascular Interventions Market Worth $702m by 2020 Says a New Report Available at MarketOptimizer.org 5Health News:A new way to generate insulin-producing cells in Type 1 diabetes 2
... to be Delayed, CAMBRIDGE, Mass., Nov. 13 ... has received a letter from the U.S.,Food and Drug ... for Synvisc-One(TM) in the United,States. The company now expects ... be delayed in the U.S. until at least the,second ...
... to avoid may offer protection , TUESDAY, Nov. 13 (HealthDay ... meats may help improve the chances of surviving a heart ... of a preliminary study in the Nov. 12 online edition ... . , Researchers found that mice fed extra nitrite ...
... house,abandoned older pets, who spend their last days watching ... kittens. November is Adopt-a-Senior-Pet Month and is dedicated ... and the fulfillment they can bring to the,right owner. ... these animals have been,surrendered," said Brent Hinton, former Kentucky ...
... water work,well for simple cleaning, they won,t do the ... illness. Something stronger must be used. U.S. Nonwovens ... this pressing problem. Rediwipes are proven to kill,99.9 percent ... "The first cardinal rule of safe food preparation in ...
... Inc.,(Nasdaq: CLRT ), a premier technology and ... today announced,that it was ranked #19 on Deloitte,s ... was also named to Deloitte,s 2007 Technology Fast ... Fast 50 is a ranking of the 50,fastest ...
... - No Human Vaccine Currently Exists Against the ... Deaths in the US so far in 2007;,Collaboration Aims ... as Rapidly as Possible Acambis plc (Acambis) (LSE: ... has signed an exclusive global,collaboration agreement with Sanofi Pasteur, ...
Cached Medicine News:Health News:Genzyme Receives FDA Response Letter on Synvisc-One(TM) 2Health News:Genzyme Receives FDA Response Letter on Synvisc-One(TM) 3Health News:Nitrite, Nitrate-Rich Foods Boost Heart Attack Outcomes 2Health News:Old Dogs Can Learn New Tricks 2Health News:Disinfecting Rediwipes(TM) Launch Targets E. coli and Salmonella 2Health News:Clarient Named to Deloitte's 2007 Orange County Technology Fast 50 for Third Consecutive Year 2Health News:Clarient Named to Deloitte's 2007 Orange County Technology Fast 50 for Third Consecutive Year 3Health News:Clarient Named to Deloitte's 2007 Orange County Technology Fast 50 for Third Consecutive Year 4Health News:Clarient Named to Deloitte's 2007 Orange County Technology Fast 50 for Third Consecutive Year 5Health News:Acambis Joins Forces With Sanofi Pasteur to Develop West Nile Virus Vaccine 2Health News:Acambis Joins Forces With Sanofi Pasteur to Develop West Nile Virus Vaccine 3Health News:Acambis Joins Forces With Sanofi Pasteur to Develop West Nile Virus Vaccine 4
Complete cytology platform....
... is the first in portability and performance. CTU ... need a flexible, portable system with the state-of-the-art features ... easily to an "E" size tank and has an ... where it is needed.,The CTU Travel Case allows you ...
The most compact revolutionary innovation in hematology. 26 parameters with 5 Part DIFF...
... Total GHb Program separates ... hemoglobin regardless of phenotype ... Schiff Base. Patient results ... DCCT reference to ensure ...
Medicine Products: